Back

Exploring the association between genetic markers and ICD discharge rate in hypertrophic cardiomyopathy

31 March 2025 (08:00 - 17:45)
Organised by: Logo
Congress Presentation Part of: Poster session 2: arrhythmia mechanisms, device therapy, and ventricular arrhythmias Epidemiology, Prognosis, Outcome EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Michael Patrick O'Shea

Mayo Clinic Hospital, Phoenix (United States of America)

146 More presentations in this session

Presentation thumbnail
Impact of ICD and CRT-D implantation on survival in ischemic and non-ischemic cardiomyopathy: a single-center croatian retrospective cohort study and comparative insights with the DANISH trial
Assistant Professor M. Puljevic (Zagreb, HR)
Abstract
Presentation thumbnail
Do the longer leadless pacemakers with helix screws affect tricuspid regurgitation after pacemaker implantation?
Presentation thumbnail
Classification of atrial fibrillation burden pattern in cardiac implantable electronic devices
Mr S. Majumder (Minneapolis, US)
Abstract Slides Video
Presentation thumbnail
Life-threatening arrhythmia in patients with suspected acute myocarditis
Miss K. Bulatova (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Early outcomes of left bundle branch area pacing upgrade in pediatric pacing-induced cardiomyopathy
Mr Y. Turubayev (Astana, KZ)
Abstract Slides Video

Access the full session

Session thumbnail
Poster session 2: arrhythmia mechanisms, device therapy, and ventricular arrhythmias

The Event

Event poster

EHRA 2025

31 March 2025 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Long-term outcomes associated with subcutaneous implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Differential genetic impact on the occurrence of atrial fibrillation in hypertrophic cardiomyopathy according to age
thumbnail
Congress Presentation
Predictors of recurrent ventricular arrhythmias and the impact of genetic testing in a hypertrophic cardiomyopathy patient cohort at long term follow up

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources